香港股市 已收市

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM 即時價格。貨幣為 USD。
加入追蹤清單
19.72-0.17 (-0.85%)
收市:04:00PM EDT
19.62 -0.10 (-0.51%)
收市後: 07:56PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價19.89
開市19.80
買盤19.71 x 300
賣出價19.76 x 600
今日波幅19.57 - 20.92
52 週波幅12.32 - 32.10
成交量684,732
平均成交量796,798
市值946.091M
Beta 值 (5 年,每月)-0.49
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.17
業績公佈日2024年8月01日 - 2024年8月05日
遠期股息及收益率無 (無)
除息日2012年12月13日
1 年預測目標價103.00
  • Zacks

    Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross

    When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  • InvestorPlace

    Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks

    Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant. Moreover, they’re probably

  • InvestorPlace

    Exit Now! 3 Biotech Stocks to Sell in February 2024

    The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas